Japan's new law advances reproductive genome editing governance

A Hiroshima University researcher outlines advantages of Japan's new law that prohibits the transfer of genome-edited human embryos or germ cells into the human reproductive tract and imposes criminal penalties for violations. The law leaves somatic gene-editing therapies unaffected and allowing basic research under legally binding oversight.

A Hiroshima University researcher contends that Japan's newly enacted law regulating human genome-edited embryos and germ cells marks a significant advance in the governance of reproductive genome editing. Tsutomu Sawai, professor at Hiroshima University's Graduate School of Humanities and Social Sciences, praises the new law for defining prohibited activities and penalties for violation but also stresses the need for stronger international coordination to prevent the prohibitions from being circumvented by individuals seeking procedures abroad.

The correspondence article was published in the journal Nature Medicine on September 8, 2026.

The law, enacted on July 17, 2026, imposes penalties on prohibited reproductive uses of genome-edited human embryos and germ cells, also known as heritable human genome editing. The prohibitions and penalties take effect on July 24, 2027-one year after the law's promulgation. While the reproductive use of heritable human genome editing had previously been disallowed in Japan, there were no legal penalties for transferring genome-edited embryos or germ cells into a uterus. While the law prohibits the reproductive use of heritable human genome editing outright, it permits the basic research of heritable human genome editing but under binding ministerial oversight.

This is an important step by Japan. Japan is already a leader in regenerative medicine, and it is expected to also be a leader in the ethics of such therapies."

Tsutomu Sawai, Professor, Hiroshima University's Graduate School of Humanities and Social Sciences

Therapies based on genome editing are still permitted

The correspondence notes that Japan's law carefully distinguishes between forms of genome editing that affect future generations and those that do not. Therefore, it does not affect the development of somatic gene-editing therapies, whose effects remain confined to the treated individual.

This distinction is important as gene-editing medicine advances rapidly. Treatments for conditions such as sickle cell disease and transfusion-dependent β-thalassemia have already been approved for patients. These therapies are unaffected by the new law and should continue to be developed through normal scientific and regulatory pathways.

International coordination is crucial

The correspondence agrees with the prohibitions, since the long-term consequences of the edits cannot be verified across multiple generations, and future children, who are most affected by these interventions, cannot consent to them in advance. However, it also warns that national prohibitions are likely insufficient and need international coordination, since people in Japan could seek heritable genome-editing procedures in countries with weaker regulations.

"No country can address heritable genome editing alone," said Sawai. "National laws are necessary, but they must be complemented by international frameworks and cooperation. The decisions we make today will affect generations that cannot speak for themselves."

At the same time, the correspondence notes that prohibitions today do not necessarily imply prohibition forever. Future developments in science, safety, and ethical understanding may justify reassessment of the law and its underlying ethical assumptions.